Mirdametinib (PD0325901) Liposomes, Formulation U6-2
LipExoGen
292 mM sucrose, 0.5% DPBS (1X)
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
10.0 mg/mL (± ~5%)
MAPK/ERK pathway
Did you look for something else?
Adavosertib Liposomes, Formulation WD4
Adavosertib Liposomes, Formulation WD4
SP600125 Liposomes, Formulation HZ12
Rocaglamide Liposomes, Formulation KHE9A
Rocaglamide Liposomes, Formulation KHE9A
Rocaglamide Liposomes, Formulation KHE9A
AZD1208 Liposomes, Formulation RB4T4
AZD1208 Liposomes, Formulation RB4T4
Lificiguat (YC-1) Liposomes, Formulation FNT8P.2
Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
Eganelisib (IPI-549) Liposomes, Formulation WNX5.2
DT-061 (SMAP) Liposomes, Formulation TT-40